The effect and safety in Telaprevir with combined peginterferon alpha-2b plus ribavirin for chronic hepatitis C patients
Not Applicable
- Conditions
- Chronic hepatitis C
- Registration Number
- JPRN-UMIN000007071
- Lead Sponsor
- Department of Hepatology, Osaka City University , Graduate School of Medicine
- Brief Summary
Telaprevir dose adjustment could prevent anemia progression without weakening the anti-viral effect during triple therapy in patients with HCV.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
The following patients were excluded women of childbearing potential and pregnancy, lactating women allergic to ribavirin or other nucleoside analogues an uncontrollable heart trouble( myocardial infarction, heart failure, or arrhythmia) hemoglobibopathy ( thalassemia, sickle cell disease) severe renal disease or Ccr<50mL/min severe depression or psychosomatic disorders severe liver disease autoimmune hepatitis or HBV drug allergy against interferon
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method